1034 related articles for article (PubMed ID: 22727222)
21. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
Gauger J; Patz EF; Coleman RE; Herndon JE
J Thorac Oncol; 2007 Jun; 2(6):499-505. PubMed ID: 17545844
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
23. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
[TBL] [Abstract][Full Text] [Related]
24. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.
Lou F; Huang J; Sima CS; Dycoco J; Rusch V; Bach PB
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):75-81; discussion 81-2. PubMed ID: 23127371
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
27. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
[TBL] [Abstract][Full Text] [Related]
28. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
[TBL] [Abstract][Full Text] [Related]
29. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
30. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
31. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
[TBL] [Abstract][Full Text] [Related]
32. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
[TBL] [Abstract][Full Text] [Related]
33. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
34. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
36. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
39. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
40. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
